7.46
0.81%
0.06
Handel nachbörslich:
7.46
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
A Tale of Resilience: Relay Therapeutics Inc Amid Stock Market Turbulence - The InvestChronicle
Renaissance Technologies LLC Buys 145,837 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics Inc (RLAY) is looking forward to a strong quarter - SETE News
1,300,000 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Acquired by Logos Global Management LP - MarketBeat
A stock that deserves closer examination: Relay Therapeutics Inc (RLAY) - US Post News
In the Green: Relay Therapeutics Inc (RLAY) Closes at 7.50, Up/Down -4.58 from Previous Day - The Dwinnex
(RLAY) Technical Data - Stock Traders Daily
Relay Therapeutics (NASDAQ:RLAY) Trading Down 4.3% - MarketBeat
HC Wainwright Weighs in on Relay Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:RLAY) - MarketBeat
A significant driver of top-line growth: Relay Therapeutics Inc (RLAY) - SETE News
Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength? - MSN
Relay Therapeutics’ (RLAY) “Market Outperform” Rating Reaffirmed at JMP Securities - Defense World
Relay Therapeutics' (RLAY) "Market Outperform" Rating Reiterated at JMP Securities - MarketBeat
Closing Figures: Relay Therapeutics Inc (RLAY)’s Positive Finish at 8.11, Up 6.71 - The Dwinnex
Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength? - Yahoo Finance
Relay Therapeutics (NASDAQ:RLAY) Given “Buy” Rating at Stifel Nicolaus - Defense World
Relay Therapeutics (NASDAQ:RLAY) Price Target Increased to $19.00 by Analysts at HC Wainwright - Defense World
Jefferies Upgrades Relay Therapeutics Inc (RLAY) to a Buy from a Hold - Knox Daily
Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion (RLAY) - Seeking Alpha
Relay Therapeutics Inc (RLAY) Stock: Navigating a Year of Volatility - The InvestChronicle
Relay Therapeutics (NASDAQ:RLAY) Receives Buy Rating from Stifel Nicolaus - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Up Following Analyst Upgrade - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) PT Raised to $19.00 - MarketBeat
Relay up 5% as Street applauds breast cancer candidate data - Seeking Alpha
Have you been able to find a good deal on Relay Therapeutics Inc’s shares? - US Post News
Relay Therapeutics shares target raised by H.C. Wainwright on trial update - Investing.com South Africa
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by TD Asset Management Inc - MarketBeat
Los Angeles Capital Management LLC Has $692,000 Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics' combo therapy cuts breast cancer progression in early study - AOL
Q3 2024 Earnings Forecast for Relay Therapeutics, Inc. (NASDAQ:RLAY) Issued By Leerink Partnrs - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Shares Down 4.4% - MarketBeat
Financial Metrics Unveiled: Relay Therapeutics Inc (RLAY)’s Key Ratios in the Spotlight - The Dwinnex
Chief Financial Officer Catinazzo Thomas sale 10,780 shares of Relay Therapeutics Inc [RLAY] - Knox Daily
Why Relay Therapeutics Plummeted by Nearly 14% Today - MSN
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down Following Analyst Downgrade - Defense World
Why Relay Therapeutics Plummeted by Nearly 14% Today - Yahoo Finance
SEC Form 424B5 filed by Relay Therapeutics Inc. - Quantisnow
Why Relay Therapeutics (RLAY) Stock Is Down 17% Today - Benzinga
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down Following Analyst Downgrade - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Now Covered by Analysts at The Goldman Sachs Group - Defense World
Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations - Seeking Alpha
Relay upgraded by Jefferies, downgraded by Oppenheimer - MSN
GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Relay Therapeutics Shares Slide Premarket on Public Offering - MarketWatch
Relay Therapeutics (NASDAQ:RLAY) Price Target Lowered to $21.00 at JPMorgan Chase & Co. - Defense World
Relay Therapeutics drops on deep-discounted $200 mln equity offering - XM
Relay Therapeutics (NASDAQ:RLAY) Upgraded to Buy at Jefferies Financial Group - Defense World
Relay Therapeutics (NASDAQ:RLAY) Lowered to “Market Perform” at Oppenheimer - Defense World
Relay Therapeutics (NASDAQ:RLAY) Given New $24.00 Price Target at Bank of America - Defense World
(RLAY) Technical Pivots with Risk Controls - Stock Traders Daily
Relay Therapeutics (NASDAQ:RLAY) Price Target Increased to $17.00 by Analysts at Barclays - Defense World
Relay Therapeutics Announces Pricing of Public Offering of Common Stock - StockTitan
Relay Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire
Relay upgraded by Jefferies, downgraded by Oppenheimer (NASDAQ:RLAY) - Seeking Alpha
Barclays slashes price target on Relay Therapeutics Inc [RLAY] – find out why. - The DBT News
Relay Therapeutics (NASDAQ:RLAY) Sees Unusually-High Trading Volume Following Analyst Upgrade - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Price Target Cut to $21.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Barclays Boosts Relay Therapeutics (NASDAQ:RLAY) Price Target to $17.00 - MarketBeat
Healthy Upside Potential: Relay Therapeutics Inc (RLAY) - SETE News
Relay Stock Soars on Upbeat Data From Breast Cancer Study - Yahoo Finance
Relay Therapeutics retreats on planned equity offering - XM
Candriam S.C.A. Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Coverage Initiated by Analysts at The Goldman Sachs Group - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Upgraded to "Buy" by Jefferies Financial Group - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Lowered to Market Perform at Oppenheimer - MarketBeat
Oppenheimer sees competition risk as Relay Therapeutics stock stumbles on trial results - Investing.com Canada
Relay Therapeutics Price Target Raised to $17 After Strong Day For The Stock (RLAY) - AskTraders
Relay Therapeutics price target raised to $24 from $20 at BofA - TipRanks
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by Candriam S.C.A. - Defense World
Jefferies bullish on Relay Therapeutics stock after positive PI3Kα inhibitor results - Investing.com
Relay Therapeutics upgraded to Buy from Hold at Jefferies - TipRanks
Oppenheimer sees competition risk as Relay Therapeutics stock stumbles on trial results - Investing.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):